According to a filing with the Singapore Exchange on Wednesday, Chan Huap's (SGX:C33) wholly-owned subsidiary, CH Biovest, saw the Court of Appeal in Singapore dismiss its appeal regarding a litigation case.
The company has now been ordered the costs of the appeal to be fixed at SG$60,000, payable to the claimants, envy asset.
In an earlier filing, the company was found liable to pay SG$2.3 million to Envy Asset, plus interest.
The suit was filed against Biovest in relation to profits paid out by Envy Asset in 2019 and 2020. Envy Asset paid Bioinvest around SG$2.3 million in order to put the assets beyond the reach of Envy Asset's creditors.
A Singaporean high court found Bioinvest is liable to pay the amount plus interest payable from Dec. 26, 2022, the date of the first demand of repayment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。